A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice

CompletedOBSERVATIONAL
Enrollment

458

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Oral semaglutide

Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.

Trial Locations (2)

00144

Master Centre for Italy, Rome

Unknown

IRCCS MultiMedica, Sesto San Giovanni

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT05230615 - A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice | Biotech Hunter | Biotech Hunter